Evidence map›Paper›PMID 39831798›Full record

ArticleeLife2025

Systematic evaluation of intratumoral and peripheral BCR repertoires in three cancers.

Sofia V Krasik, Ekaterina A Bryushkova, George V Sharonov, Daria S Myalik, Elizaveta V Shurganova, Dmitry V Komarov, Irina A Shagina, Polina S Shpudeiko, Maria A Turchaninova, Maria T Vakhitova and 6 more

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. AnalyzAIRR: A user-friendly guided workflow for AIRR data analysis.Immunoinformatics (Amsterdam, Netherlands) · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sofia V Krasik *Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russian Federation.
Ekaterina A Bryushkova *Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation.
George V SharonovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation.ORCID https://orcid.org/0000-0001-8610-5054
Daria S MyalikPrivolzhsky Research Medical University, Nizhny Novgorod, Russian Federation.
Elizaveta V ShurganovaPrivolzhsky Research Medical University, Nizhny Novgorod, Russian Federation.
Dmitry V KomarovVolga Regional Medical Centre Under Federal Medical and Biological Agency, Nizhny Novgorod, Russian Federation.
Irina A ShaginaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation.
Polina S ShpudeikoDepartment of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russian Federation.
Maria A TurchaninovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation.
Maria T VakhitovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation.
Igor V SamoylenkoFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russian Federation, Moscow, Russian Federation.
Dimitr T MarinovFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russian Federation, Moscow, Russian Federation.
Lev V DemidovFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russian Federation, Moscow, Russian Federation.
Vladimir E ZagaynovPrivolzhsky Research Medical University, Nizhny Novgorod, Russian Federation.
Dmitriy M ChudakovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation.ORCID https://orcid.org/0000-0003-0430-790X
Ekaterina O SerebrovskayaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation.ORCID https://orcid.org/0000-0002-4967-7165

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2019-1789
6 · The paper itself

Abstract

The current understanding of humoral immune response in cancer patients suggests that tumors may be infiltrated with diffuse B cells of extra-tumoral origin or may develop organized lymphoid structures, where somatic hypermutation and antigen-driven selection occur locally. These processes are believed to be significantly influenced by the tumor microenvironment through secretory factors and biased cell-cell interactions. To explore the manifestation of this influence, we used deep unbiased immunoglobulin profiling and systematically characterized the relationships between B cells in circulation, draining lymph nodes (draining LNs), and tumors in 14 patients with three human cancers. We demonstrated that draining LNs are differentially involved in the interaction with the tumor site, and that significant heterogeneity exists even between different parts of a single lymph node (LN). Next, we confirmed and elaborated upon previous observations regarding intratumoral immunoglobulin heterogeneity. We identified B cell receptor (BCR) clonotypes that were expanded in tumors relative to draining LNs and blood and observed that these tumor-expanded clonotypes were less hypermutated than non-expanded (ubiquitous) clonotypes. Furthermore, we observed a shift in the properties of complementarity-determining region 3 of the BCR heavy chain (CDR-H3) towards less mature and less specific BCR repertoire in tumor-infiltrating B-cells compared to circulating B-cells, which may indicate less stringent control for antibody-producing B cell development in tumor microenvironment (TME). In addition, we found repertoire-level evidence that B-cells may be selected according to their CDR-H3 physicochemical properties before they activate somatic hypermutation (SHM). Altogether, our work outlines a broad picture of the differences in the tumor BCR repertoire relative to non-tumor tissues and points to the unexpected features of the SHM process.

Indexed as

B-LymphocytesNeoplasmsReceptors, Antigen, B-CellFemaleHumansLymph NodesMaleTumor MicroenvironmentReceptors, Antigen, B-CellBCRcancer biologyhumanhypermutationimmunoglobulinimmunologyinflammationtumor infiltrating B cells

Identifiers

PMID39831798
PMCPMC11745494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.